Myeloma UK as a driver of collaboration between industry and academia
Revisiting clinical trial design – more adaptability in Phase I – III?
Elihu H. Estey
The real cost of hematological cancer care explained
The 20th anniversary of the German CLL Study Group and the importance of collaboration
The price of new innovation for the treatment of multiple myeloma